Animal Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

The Global Animal Vaccines Market was valued at USD 9.9 billion in 2024 and is estimated to grow at a CAGR of 6.9% to reach USD 19 billion by 2034. The global demand for animal vaccines is on the rise as concerns over animal health and food safety gain increasing prominence. With the growing emphasis on preventing zoonotic diseases and reducing economic losses from animal disease outbreaks, the importance of vaccination programs has grown multifold. A steady rise in the global animal population, along with the increasing trend of pet adoption and ownership, is reshaping how veterinary care is perceived and prioritized. Pet owners today are more inclined to invest in preventive healthcare, including vaccinations, to ensure longer and healthier lives for their companion animals. At the same time, livestock farmers are adopting proactive immunization strategies to safeguard their herds against highly contagious diseases that can cripple supply chains and impact international trade. Governments across the globe are tightening regulations related to animal health, implementing compulsory vaccination programs to protect animal welfare, secure the food supply chain, and minimize the risk of cross-species disease transmission. This broader awareness of animal health as an integral part of public health is significantly contributing to market growth.

The animal vaccines market is broadly segmented into two key categories: livestock and companion animals. In 2024, the livestock category dominated the market with a valuation of USD 6.4 billion. Livestock species such as poultry, cattle, swine, and aquaculture are critical to global food security and agricultural economies. Preventing disease outbreaks in these animals is crucial to maintaining productivity and minimizing financial losses. Incidences of foot-and-mouth disease, swine fever, and avian influenza remain serious concerns in this sector, reinforcing the need for robust vaccination strategies. While the companion animal segment is also expanding due to rising pet ownership and increased attention to pet wellness, the livestock segment continues to generate the highest revenue.

Vaccines in the animal health sector include several types, such as attenuated live, conjugate, inactivated, DNA, recombinant, and others. Among these, attenuated live vaccines held the highest market share in 2024, accounting for 44.1% of the total. These vaccines are widely favored for their ability to produce strong immune responses and deliver long-term protection. Their capability to stimulate both humoral and cell-mediated immunity often reduces the need for repeated doses, making them a preferred option in both livestock and companion animal vaccination programs.

North America accounted for 40.6% of the global animal vaccines market in 2024. This dominant share is driven by a large population of domesticated animals and livestock in the region. The United States leads in pet ownership and has a well-established agricultural sector comprising cattle, poultry, and swine. The ongoing focus on maintaining herd health and minimizing infectious disease risks continues to drive vaccine adoption in the region.

Key players shaping the global animal vaccine landscape include Zoetis, Merck Animal Health, Virbac, Boehringer Ingelheim International, Bioveta, Brilliant Bio Pharma, Dechra Pharmaceuticals, Vetoquinol, Neogen Corporation, Elanco Animal Health, Hipra Animal Health Limited, and Henry Schein Animal Health (Covetrus, Inc.). These companies are actively expanding their vaccine portfolios through extensive research and development. Strategic partnerships with veterinary organizations and government agencies are helping improve vaccine accessibility. Additionally, the adoption of advanced technologies like genetic engineering and recombinant DNA is enabling the creation of more effective, long-lasting vaccines tailored to evolving disease threats.